telenzepine has been researched along with Chronic Disease in 2 studies
telenzepine: structure given in first source
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of an M1-selective muscarinic receptor antagonist telenzepine on lung function was investigated in 18 patients with chronic obstructive bronchitis in a double blind, placebo-controlled, randomized crossover study." | 9.06 | An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. ( Cazzola, M; D'Amato, G; Guidetti, E; Kilian, U; Staudinger, H; Steinijans, VW, 1990) |
| "3 mg telenzepine was well tolerated." | 5.28 | [Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis]. ( Dammann, HG; Müller, P; Reinicke, A; Simon, B, 1990) |
| "The effect of an M1-selective muscarinic receptor antagonist telenzepine on lung function was investigated in 18 patients with chronic obstructive bronchitis in a double blind, placebo-controlled, randomized crossover study." | 5.06 | An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. ( Cazzola, M; D'Amato, G; Guidetti, E; Kilian, U; Staudinger, H; Steinijans, VW, 1990) |
| "3 mg telenzepine was well tolerated." | 1.28 | [Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis]. ( Dammann, HG; Müller, P; Reinicke, A; Simon, B, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reinicke, A | 1 |
| Müller, P | 1 |
| Dammann, HG | 1 |
| Simon, B | 1 |
| Cazzola, M | 1 |
| D'Amato, G | 1 |
| Guidetti, E | 1 |
| Staudinger, H | 1 |
| Steinijans, VW | 1 |
| Kilian, U | 1 |
1 trial available for telenzepine and Chronic Disease
| Article | Year |
|---|---|
An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis.
Topics: Administration, Oral; Adult; Aged; Biometry; Bronchitis; Chronic Disease; Double-Blind Method; Femal | 1990 |
1 other study available for telenzepine and Chronic Disease
| Article | Year |
|---|---|
[Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis].
Topics: Adolescent; Adult; Chronic Disease; Half-Life; Humans; Liver Cirrhosis; Middle Aged; Parasympatholyt | 1990 |